All Updates

All Updates

icon
Filter
Funding
SphingoTec raises EUR 5 million in Series C funding for marketing and licensing activities
Precision Medicine
Aug 8, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Microsoft launches Face Check with Microsoft Entra Verified ID
Facial Recognition
Sep 11, 2024
Funding
3DEO raises USD 3.5 million in strategic investment from Mizuho Bank
Additive Manufacturing
Sep 6, 2024
Product updates
HyperWrite launches open-source AI model Reflection 70 billion
Generative AI Applications
Sep 5, 2024
Product updates
Google begins US rollout of AI-powered Ask Photos feature
Generative AI Applications
Sep 5, 2024
Funding
Management news
HDAX Therapeutics raises USD 3.2 million in seed funding to progress pipeline and advance preclinical candidates into trials
Precision Medicine
Sep 5, 2024
Partnerships
Sequentify partners with Dexter to expand genomic diagnostics in Romania
Precision Medicine
Sep 5, 2024
Partnerships
Elevate partners with Cultivatd for European expansion
Vertical Farming
Sep 5, 2024
Product updates
Moolec confirms harvest of its genetically engineered plant-grown products
Crop Biotech
Sep 5, 2024
Precision Medicine

Precision Medicine

Aug 8, 2024

SphingoTec raises EUR 5 million in Series C funding for marketing and licensing activities

Funding

  • SphingoTec has raised EUR 5 million (~USD 5.5 million) in a Series C round led by Think.Health Ventures, with participation from existing investors such as Brandenburg Kapital, HBM Healthcare Investments, NRW.BANK, and Wellington Partners.

  • The funds will be directed to further its market development, advance out-licensing activities, and facilitate strong cooperation with licensees. The company also plans to diversify its biomarker-based diagnostic solutions and enhance patient management in critical care.

  • Germany-based SphingoTec is a diagnostic company focused on developing innovative critical care biomarkers for diagnosing, predicting, and monitoring acute medical conditions. Its proprietary biomarker portfolio includes Proenkephalin A 119-159 (penKid), a biomarker for assessing kidney function in critical diseases, and bioactive Adrenomedullin 1-52 (bio-ADM), a biomarker for assessing endothelial function in conditions like sepsis.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.